Search

Displaying results 441 - 450 of 7555 in total
  1. Drug

    Levofloxacin

    go.drugbank.com/drugs/DB01137
    ApprovedInvestigational

    [A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.[A190663] … (i.e. it does not invert to the inactive isomer).

    Products: NEO LEVO
  2. Drug

    Testosterone enanthate

    go.drugbank.com/drugs/DB13944
    ApprovedInvestigational

    This slow release is achieved by the presence of the enanthate ester functional group attached to the testosterone molecule. … [A31615] This testosterone derivative was first approved on December 24, 1953.[L8941] In 2017, about 6.5 million retail prescriptions for testosterone therapy were filled [L4659].

    Mixtures: Neo Pause Injection
  3. Indication

    Hodgkin's Lymphoma

    go.drugbank.com/conditions/DBCOND0030382
    Drugs: Bleomycin · Chlorambucil · Cyclophosphamide · Dacarbazine · Doxorubicin · Gemcitabine +5 more
    Synonyms: Hodgkin lymphoma, no ICD-O subtype, Hodgkin lymphoma, no ICD-O subtype (morphologic abnormality)
  4. Indication

    Lymphoma, Low-Grade

    go.drugbank.com/conditions/DBCOND0029914
    Drugs: Interferon alfa-2a · Loncastuximab tesirine
    Synonyms: Non-Hodgkin lymphoma, no ICD-O subtype, Non-Hodgkin lymphoma, no ICD-O subtype (morphologic abnormality)
  5. Drug

    Migalastat

    go.drugbank.com/drugs/DB05018
    ApprovedInvestigational

    [L47036,L47057,L4274,L4278] In these patients, migalastat works by stabilizing the body’s dysfunctional alpha-Gal A enzyme so that it can clear the accumulation of glycosphingolipid disease substrate. … Fabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A).

  6. Drug

    Flibanserin

    go.drugbank.com/drugs/DB04908
    ApprovedInvestigational

    It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals … Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  7. Indication

    Haemangioma

    go.drugbank.com/conditions/DBCOND0017266
    Drugs: Propranolol · Triamcinolone
    Synonyms: Hemangioma, no ICD-O subtype, Hemangioma, no International Classification of Diseases for Oncology subtype
  8. Indication

    Cutaneous Squamous Cell Carcinoma (CSCC)

    go.drugbank.com/conditions/DBCOND0168836
    Drugs: Cemiplimab
    Synonyms: Squamous cell carcinoma, no ICD-O subtype, Squamous cell carcinoma, no International Classification of Diseases for Oncology subtype
  9. Drug

    Oxamniquine

    go.drugbank.com/drugs/DB01096
    Approved

    Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs. … An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp.

  10. Drug

    Candesartan cilexetil

    go.drugbank.com/drugs/DB00796
    ApprovedInvestigational

    Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents … Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough.

    Mixtures: Nb-candesartan HCT, Nb-candesartan HCTCategories: Agents Acting on the Renin-Angiotensin System